BTIG Research Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR)

Key Points

• BTIG Research has reiterated a "buy" rating for Monopar Therapeutics (NASDAQ:MNPR) with a price target of $87.00, indicating a potential upside of 76.21% from its previous close.
• Monopar's stock has shown significant volatility, with a 12-month high of $54.30 and a low of $3.65, alongside a current market cap of approximately $304.64 million.
• Insider transactions indicate active trading, with both the CEO and a director selling shares at $40.00 each, resulting in a notable decrease in their ownership stakes.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at BTIG Research in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $87.00 target price on the stock. BTIG Research's price objective points to a potential upside of 37.36% from the stock's current price.

MNPR has been the topic of a number of other reports. Chardan Capital reiterated a "buy" rating and set a $60.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, August 13th. HC Wainwright began coverage on shares of Monopar Therapeutics in a research note on Tuesday, August 26th. They set a "buy" rating and a $70.00 price objective on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $74.00 target price on shares of Monopar Therapeutics in a report on Wednesday, August 27th. Wall Street Zen raised shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, Oppenheimer began coverage on shares of Monopar Therapeutics in a report on Wednesday, September 3rd. They set an "outperform" rating and a $77.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $71.75.

Monopar Therapeutics Stock Performance

Shares of MNPR stock traded down $2.91 on Monday, hitting $63.34. The stock had a trading volume of 24,342 shares, compared to its average volume of 40,666. Monopar Therapeutics has a 52-week low of $4.12 and a 52-week high of $68.18. The firm has a market capitalization of $390.80 million, a price-to-earnings ratio of -18.96 and a beta of 1.20. The stock's 50 day moving average is $41.13 and its 200-day moving average is $37.70.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.12. Equities analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Christopher M. Starr sold 16,800 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the sale, the director directly owned 5,173 shares in the company, valued at approximately $206,920. This trade represents a 76.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $356,160.00. Following the sale, the director owned 11,486 shares of the company's stock, valued at approximately $459,440. This represents a 43.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 42,504 shares of company stock worth $1,700,160. 20.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. bought a new position in Monopar Therapeutics during the fourth quarter valued at approximately $3,694,000. Geode Capital Management LLC raised its position in Monopar Therapeutics by 99.7% during the second quarter. Geode Capital Management LLC now owns 96,919 shares of the company's stock valued at $3,468,000 after acquiring an additional 48,379 shares in the last quarter. Affinity Asset Advisors LLC raised its position in Monopar Therapeutics by 8.9% during the second quarter. Affinity Asset Advisors LLC now owns 67,500 shares of the company's stock valued at $2,415,000 after acquiring an additional 5,500 shares in the last quarter. Goldman Sachs Group Inc. bought a new position in Monopar Therapeutics during the first quarter valued at approximately $673,000. Finally, Jane Street Group LLC bought a new position in Monopar Therapeutics during the first quarter valued at approximately $377,000. Institutional investors own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.